top of page


We continue to be at the forefront of a powerful form of immunotherapy known as chimeric antigen receptor (CAR) T cell therapy.  Using this approach, immune cells are taken from a patient’s bloodstream, reprogrammed to recognize and attack a specific protein found in cancer cells, then reintroduced into the patient’s system, where they get to work destroying targeted tumor cells.

Oasis has established an advanced technological platform for clinical-grade CAR-T cell preparation and has developed a number of candidate CAR-T cellular products that address both hard and soft tumors.  


bottom of page